FDA Warning Letters
This article was originally published in The Silver Sheet
Executive Summary
WARNING LETTERS: Medtronic cited for QS and MDR violations in relation to its SynchroMed II infusion pumps and MiniMed Paradigm insulin pumps
You may also be interested in...
Medtronic recalls infusion sets
Medtronic is recalling specific lots of its Quick-set infusion set used with MiniMed Paradigm insulin pumps. The set is a replaceable plastic tube that delivers insulin from the pump to the patient. Medtronic recently discovered that about 2 percent of the sets in a lot of about 60,000 may not allow the pump to vent air properly, which could cause the device to deliver the wrong amount of insulin. Medtronic is advising patients to check http://www.medtronicdiabetes.com/ to see which box numbers have been recalled. The company will replace the affected products for free. Medtronic estimates about 3 million Quick-set sets are currently in use. Meanwhile, the company received a June 1 FDA warning letter in relation to its MiniMed pumps. (See "Warning Letters"
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.